Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 11:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,233 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Chronic Obstructive Pulmonary Disease COPD Clear all
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Effects of Broccoli Sprout Extract on Obstructive Lung Disease

NCT00994604
View directory record Official record
Conditions
Asthma, COPD
Interventions
broccoli sprout extract
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 27, 2017 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02155660
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Benralizumab Arm C, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
2,255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
151
States / cities
Birmingham, Alabama • Gulf Shores, Alabama • Montgomery, Alabama + 127 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 15, 2026, 11:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

NCT00568347
View directory record Official record
Conditions
COPD
Interventions
fluticasone 100mcg/ salmeterol 50mcg, fluticasone 250/salmeterol 50, Salmeterol, salmeterol and fluticasone propionate
Drug
Lead sponsor
Arthur F Gelb MD
Individual
Eligibility
20 Years to 85 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2013
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 15, 2026, 11:13 PM EDT
Terminated Phase 3 Interventional Results available

Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency

NCT02722304
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency
Interventions
ARALAST NP 60 mg/kg, ARALAST NP 120 mg/kg, GLASSIA 60 mg/kg, GLASSIA 120 mg/kg, Human Albumin 2%
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
14
States / cities
Peoria, Arizona • Newport Beach, California • Kissimmee, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 15, 2026, 11:13 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

NCT01793649
View directory record Official record
Conditions
Cystic Fibrosis, Chronic Obstructive Pulmonary Disease
Interventions
GS-5737
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 20, 2014 · Synced Oct 15, 2026, 11:13 PM EDT
Suspended Phase 1 Interventional

Use of Autologous Stem/Stromal Cells In Chronic Lung Disorders: Obstructive (COPD) & Restrictive (RLD)

NCT03909750
View directory record Official record
Conditions
COPD, Respiratory Insufficiency
Interventions
Lipoaspiration, AD-cSVF, Normal Saline IV
Procedure
Lead sponsor
Healeon Medical Inc
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Stevensville, Montana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2024 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History

NCT02138916
View directory record Official record
Conditions
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Interventions
Benralizumab Arm A, Benralizumab Arm B, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
138
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 114 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Oct 15, 2026, 11:13 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Palliative Care Health Literacy Education and QOL Compared to Usual Care

NCT06089499
View directory record Official record
Conditions
COPD
Interventions
Get Palliative Care: four educational learning module videos
Behavioral
Lead sponsor
University of Missouri, Kansas City
Other
Eligibility
65 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 2 Interventional Results available

Investigation of Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of Oral Danirixin in Symptomatic COPD Subjects With Mild to Moderate Airflow Limitation at Risk for Exacerbations

NCT02130193
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Danirixin, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Iowa City, Iowa + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 11:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Innate Immunity in Ozone-induced Airway Inflammation in COPD

NCT04669743
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Airway Disease, COPD Exacerbation, Pollution; Exposure, Pollution Related Respiratory Disorder
Interventions
Ozone exposure
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
45 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 15, 2026, 11:13 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Prospective Observational Study of the Breath Responsive Variable Bolus Oxygen Conserving Device

NCT02627599
View directory record Official record
Conditions
COPD
Interventions
Breath Responsive Variable Bolus Oxygen Conserving Device
Device
Lead sponsor
StratiHealth
Industry
Eligibility
65 Years to 85 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Oceanside, California • Vista, California • Westminster, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2018 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Tiotropium / Respimat One-Year Study

NCT00168844
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Tiotropium Inhalation Solution, Placebo
Drug · Other
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
983 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
12
States / cities
Los Angeles, California • Pismo Beach, California • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

A Study Characterizing Pharmacodynamic Profiles in Subjects With Chronic Obstructive Pulmonary Disease

NCT01113593
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Formoterol Fumarate, Foradil Aerolizer
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Clearwater, Florida • DeLand, Florida • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 27, 2013 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 3 Interventional Results available

Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

NCT03930732
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Dupilumab SAR231893, Inhaled Corticosteroid, Inhaled Long-Acting Beta Agonist, Inhaled Long-Acting Muscarinic Antagonist, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
40 Years to 80 Years
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
51
States / cities
Andalusia, Alabama • Birmingham, Alabama • Dothan, Alabama + 46 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Total Systemic Exposure Bioequivalence of of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

NCT05569421
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 60 Years
Enrollment
108 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Evaluation of Auto-EPAP for Management of Upper Airway Obstruction During Non-Invasive Ventilation

NCT06560411
View directory record Official record
Conditions
Obstructive Sleep Apnea, Obesity Hypoventilation Syndrome (OHS), Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Diseases (NMD)
Interventions
Non-Invasive Ventilation
Device
Lead sponsor
Breas Medical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Scottsdale, Arizona • San Diego, California • Colorado Springs, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact of a Mobile Phone and Educational Intervention

NCT06878898
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Asthma COPD
Interventions
Education and mobile phone text-messaging, Education only
Behavioral · Other
Lead sponsor
Kent State University
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Kent, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Hydrolyzed Casein and Whey Protein Supplementation and the Addition of Leucine to Induce Protein Anabolism in Malnourished COPD Patients

NCT01154400
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Casein protein hydrolysates, Whey protein hydrolysates, Casein protein hydrolysates + LEU, Whey protein hydrolysates + LEU
Dietary Supplement
Lead sponsor
Texas A&M University
Other
Eligibility
45 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2012 · Synced Oct 15, 2026, 11:13 PM EDT
Not listed No phase listed Observational

Steroid Resistance During COPD Exacerbations With Respiratory Failure

NCT03680495
View directory record Official record
Conditions
COPD, Emphysema or COPD, COPD Exacerbation, COPD Exacerbation Acute, Respiratory Failure, Ventilatory Failure
Interventions
Methylprednisolone
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years to 89 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 15, 2026, 11:13 PM EDT
Completed No phase listed Observational

Validation of PROMIS Banks With COPD Exacerbations

NCT00784342
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
5
States / cities
Evanston, Illinois • Chapel Hill, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2012 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Not applicable Interventional

Sustained Effects of Hypertonic Saline on Mucociliary Clearance in Subjects With Chronic Bronchitis

NCT01792271
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD, Chronic Bronchitis
Interventions
Inhaled 7% HS (NaCl) home treatment
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
40 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 2 Interventional

Efficacy of Osteopathic Manipulation in Chronic Obstructive Pulmonary Disease

NCT00034112
View directory record Official record
Conditions
Emphysema
Interventions
osteopathic manipulative treatment
Procedure
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
Kirksville, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 18, 2006 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Assessment In a Real World Setting of the Effect of Inhaled Steroid-based Triple Therapy Versus the Combination of Tiotropium and Olodaterol on Reducing Chronic Obstructive Pulmonary Disease (COPD) Exacerbations [AIRWISE]

NCT03265145
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Stiolto Respimat, ICS (Inhaled Corticosteroid) (Triple therapy), LABA (Long-Acting Beta Agonist) (Triple therapy), LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
90
States / cities
Mobile, Alabama • Montgomery, Alabama • Tucson, Arizona + 84 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 15, 2026, 11:13 PM EDT
Completed Phase 4 Interventional Results available

Tiotropium In Exercise

NCT00525512
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive, Exercise
Interventions
tiotropium 18 mcg, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
519 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
21
States / cities
Jasper, Alabama • Phoenix, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 24, 2013 · Synced Oct 15, 2026, 11:13 PM EDT